IVAL is proud to present our products and contract services to you that represent our past three decades of expertise in the application of in vitro experimental systems to evaluate drug absorption, metabolism, drug-drug interactions and drug toxicity.Besides the routine in vitro ADME studies that are also offered by other contract research organizations, we have developed higher throughput screening assays to aid the selection of best drug candidates for during early phases of drug development: organ-specific toxicity evaluation (e.g. hepatotoxicity; nephrotoxicity; neurotoxicity) using primary cells; sDILI (severe Drug Induced Liver Injury) screen; multi-species (human, rat, dog, monkey and mice) hepatotoxicity screen; metabolic stability of low turnover compounds; metabolite identification; long term mechanistic toxicity evaluation using 3-D hepatocytes (spheroids); human hepatocyte P450 inhibition assays, and human hepatocyte P450 induction assays; as well as a comprehensive screening assay for adverse drug properties.
Our products that are widely used in early drug discovery toxicity, drug metabolism and pharmacokinetics (DMPK) include primary cryopreserved hepatocytes from humans, animals such as rat, mice, dog and monkey, collagen coated multi-well format plates (6 well, 12-well, 24-well, 48-well, 96-well & 384-well), media (hepatocyte recovery media (UCRM), plating media (UPCM), maintainence media (LDMM)), primary human and animal enterocytes, renal proximal tubule cells.